{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:34:41Z","timestamp":1781789681571,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90159-0","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T11:49:26Z","timestamp":1739620166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of ECE2 signaling in promoting non-small lung cancer progression through ET1\/YAP1\/MAGEA3 axis"],"prefix":"10.1038","volume":"15","author":[{"given":"Huaiqing","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"90159_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F. & Wong, K. K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 14, 535\u2013546. https:\/\/doi.org\/10.1038\/nrc3775 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"90159_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","volume":"52","author":"L Osmani","year":"2018","unstructured":"Osmani, L., Askin, F., Gabrielson, E. & Li, Q. K. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin. Cancer Biol. 52, 103\u2013109. https:\/\/doi.org\/10.1016\/j.semcancer.2017.11.019 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"90159_CR3","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma, N., Santana-Davila, R. & Molina, J. R. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin. Proc. 94, 1623\u20131640. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.013 (2019).","journal-title":"Mayo Clin. Proc."},{"key":"90159_CR4","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.Can-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw, D. C. & Shevde, L. A. The tumor microenvironment innately modulates cancer progression. Cancer Res. 79, 4557\u20134566. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-3962 (2019).","journal-title":"Cancer Res."},{"key":"90159_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11906-008-0013-2","volume":"10","author":"DE Kohan","year":"2008","unstructured":"Kohan, D. E. Endothelin-1 and hypertension: from bench to bedside. Curr. Hypertens. Rep. 10, 65\u201369. https:\/\/doi.org\/10.1007\/s11906-008-0013-2 (2008).","journal-title":"Curr. Hypertens. Rep."},{"key":"90159_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1476-5381.2012.02195.x","volume":"168","author":"FM Drawnel","year":"2013","unstructured":"Drawnel, F. M., Archer, C. R. & Roderick, H. L. The role of the paracrine\/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth. Br. J. Pharmacol. 168, 296\u2013317. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.02195.x (2013).","journal-title":"Br. J. Pharmacol."},{"key":"90159_CR7","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/hypertensionaha.119.12105","volume":"74","author":"M Barton","year":"2019","unstructured":"Barton, M. & Yanagisawa, M. Endothelin: 30 years from discovery to therapy. Hypertension 74, 1232\u20131265. https:\/\/doi.org\/10.1161\/hypertensionaha.119.12105 (2019).","journal-title":"Hypertension"},{"key":"90159_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1172\/jci42912","volume":"121","author":"N Said","year":"2011","unstructured":"Said, N., Smith, S., Sanchez-Carbayo, M. & Theodorescu, D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J. Clin. Invest. 121, 132\u2013147. https:\/\/doi.org\/10.1172\/jci42912 (2011).","journal-title":"J. Clin. Invest."},{"key":"90159_CR9","doi-asserted-by":"publisher","first-page":"27850","DOI":"10.1074\/jbc.M202421200","volume":"277","author":"F Spinella","year":"2002","unstructured":"Spinella, F., Rosan\u00f2, L., Di Castro, V., Natali, P. G. & Bagnato, A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J. Biol. Chem. 277, 27850\u201327855. https:\/\/doi.org\/10.1074\/jbc.M202421200 (2002).","journal-title":"J. Biol. Chem."},{"key":"90159_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3389\/fonc.2019.00928","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. Systematic profiling of alternative mRNA splicing signature for predicting glioblastoma prognosis. Front. Oncol. 9, 928. https:\/\/doi.org\/10.3389\/fonc.2019.00928 (2019).","journal-title":"Front. Oncol."},{"key":"90159_CR11","doi-asserted-by":"publisher","first-page":"14343","DOI":"10.1038\/ncomms14343","volume":"8","author":"IS Kim","year":"2017","unstructured":"Kim, I. S. et al. Microenvironment-derived factors driving metastatic plasticity in melanoma. Nat. Commun. 8, 14343. https:\/\/doi.org\/10.1038\/ncomms14343 (2017).","journal-title":"Nat. Commun."},{"key":"90159_CR12","doi-asserted-by":"publisher","first-page":"14704","DOI":"10.1074\/jbc.M211242200","volume":"278","author":"N Mzhavia","year":"2003","unstructured":"Mzhavia, N., Pan, H., Che, F. Y., Fricker, L. D. & Devi, L. A. Characterization of endothelin-converting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides. J. Biol. Chem. 278, 14704\u201314711. https:\/\/doi.org\/10.1074\/jbc.M211242200 (2003).","journal-title":"J. Biol. Chem."},{"key":"90159_CR13","doi-asserted-by":"publisher","first-page":"15262","DOI":"10.1074\/jbc.270.25.15262","volume":"270","author":"N Emoto","year":"1995","unstructured":"Emoto, N. & Yanagisawa, M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J. Biol. Chem. 270, 15262\u201315268. https:\/\/doi.org\/10.1074\/jbc.270.25.15262 (1995).","journal-title":"J. Biol. Chem."},{"key":"90159_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc3546","volume":"13","author":"L Rosan\u00f2","year":"2013","unstructured":"Rosan\u00f2, L., Spinella, F. & Bagnato, A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 13, 637\u2013651. https:\/\/doi.org\/10.1038\/nrc3546 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"90159_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2011.01217.x","volume":"163","author":"A Bagnato","year":"2011","unstructured":"Bagnato, A., Loizidou, M., Pflug, B. R., Curwen, J. & Growcott, J. Role of the endothelin axis and its antagonists in the treatment of cancer. Br. J. Pharmacol. 163, 220\u2013233. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01217.x (2011).","journal-title":"Br. J. Pharmacol."},{"key":"90159_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1034\/j.1600-065x.2002.18803.x","volume":"188","author":"MJ Scanlan","year":"2002","unstructured":"Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J. & Chen, Y. T. Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22\u201332. https:\/\/doi.org\/10.1034\/j.1600-065x.2002.18803.x (2002).","journal-title":"Immunol. Rev."},{"key":"90159_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcancer.2018.08.006","volume":"53","author":"O Gordeeva","year":"2018","unstructured":"Gordeeva, O. Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy. Semin. Cancer Biol. 53, 75\u201389. https:\/\/doi.org\/10.1016\/j.semcancer.2018.08.006 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"90159_CR18","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/0008-5472.Can-16-3229","volume":"77","author":"Z Wang","year":"2017","unstructured":"Wang, Z. et al. Endothelin promotes colorectal tumorigenesis by activating YAP\/TAZ. Cancer Res. 77, 2413\u20132423. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-3229 (2017).","journal-title":"Cancer Res."},{"key":"90159_CR19","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1002\/cam4.3024","volume":"9","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. Sitagliptin affects gastric cancer cells proliferation by suppressing melanoma-associated antigen-A3 expression through yes-associated protein inactivation. Cancer Med. 9, 3816\u20133828. https:\/\/doi.org\/10.1002\/cam4.3024 (2020).","journal-title":"Cancer Med."},{"key":"90159_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.critrevonc.2013.08.011","volume":"89","author":"S Irani","year":"2014","unstructured":"Irani, S., Salajegheh, A., Smith, R. A. & Lam, A. K. A review of the profile of endothelin axis in cancer and its management. Crit. Rev. Oncol. Hematol. 89, 314\u2013321. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.011 (2014).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"90159_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/sj.bjc.6700750","volume":"88","author":"K Grant","year":"2003","unstructured":"Grant, K., Loizidou, M. & Taylor, I. Endothelin-1: a multifunctional molecule in cancer. Br. J. Cancer 88, 163\u2013166. https:\/\/doi.org\/10.1038\/sj.bjc.6700750 (2003).","journal-title":"Br. J. Cancer"},{"key":"90159_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2174\/157016105774329462","volume":"3","author":"J Knowles","year":"2005","unstructured":"Knowles, J., Loizidou, M. & Taylor, I. Endothelin-1 and angiogenesis in cancer. Curr. Vasc. Pharmacol. 3, 309\u2013314. https:\/\/doi.org\/10.2174\/157016105774329462 (2005).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"90159_CR23","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1158\/0008-5472.Can-08-2093","volume":"68","author":"O Rayhman","year":"2008","unstructured":"Rayhman, O. et al. Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res. 68, 9265\u20139273. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-2093 (2008).","journal-title":"Cancer Res."},{"key":"90159_CR24","doi-asserted-by":"publisher","first-page":"R469","DOI":"10.1152\/ajpregu.00532.2015","volume":"310","author":"L Rosan\u00f2","year":"2016","unstructured":"Rosan\u00f2, L. & Bagnato, A. Endothelin therapeutics in cancer: Where are we?. Am. J. Physiol. Regul. Integr. Comp. Physiol. 310, R469-475. https:\/\/doi.org\/10.1152\/ajpregu.00532.2015 (2016).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"90159_CR25","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/ijc.21656","volume":"118","author":"J Kim","year":"2006","unstructured":"Kim, J. et al. The clinical significance of MAGEA3 expression in pancreatic cancer. Int. J. Cancer 118, 2269\u20132275. https:\/\/doi.org\/10.1002\/ijc.21656 (2006).","journal-title":"Int. J. Cancer"},{"key":"90159_CR26","doi-asserted-by":"publisher","first-page":"114700","DOI":"10.1016\/j.bcp.2021.114700","volume":"192","author":"P Sch\u00e4fer","year":"2021","unstructured":"Sch\u00e4fer, P., Paraschiakos, T. & Windhorst, S. Oncogenic activity and cellular functionality of melanoma associated antigen A3. Biochem. Pharmacol. 192, 114700. https:\/\/doi.org\/10.1016\/j.bcp.2021.114700 (2021).","journal-title":"Biochem. Pharmacol."},{"key":"90159_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s13402-015-0261-5","volume":"39","author":"C Xie","year":"2016","unstructured":"Xie, C. et al. Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer. Cell. Oncol. (Dordr.) 39, 175\u2013186. https:\/\/doi.org\/10.1007\/s13402-015-0261-5 (2016).","journal-title":"Cell. Oncol. (Dordr.)"},{"key":"90159_CR28","doi-asserted-by":"publisher","first-page":"8104","DOI":"10.1158\/0008-5472.Can-08-2132","volume":"68","author":"W Liu","year":"2008","unstructured":"Liu, W., Cheng, S., Asa, S. L. & Ezzat, S. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res. 68, 8104\u20138112. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-2132 (2008).","journal-title":"Cancer Res."},{"key":"90159_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1517\/14712598.2014.880421","volume":"14","author":"V Adam","year":"2014","unstructured":"Adam, V., Wauters, I. & Vansteenkiste, J. Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer. Expert Opin. Biol. Ther. 14, 365\u2013376. https:\/\/doi.org\/10.1517\/14712598.2014.880421 (2014).","journal-title":"Expert Opin. Biol. Ther."},{"key":"90159_CR30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/s1470-2045(16)00099-1","volume":"17","author":"JF Vansteenkiste","year":"2016","unstructured":"Vansteenkiste, J. F. et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 17, 822\u2013835. https:\/\/doi.org\/10.1016\/s1470-2045(16)00099-1 (2016).","journal-title":"Lancet Oncol."},{"key":"90159_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","volume":"29","author":"F Zanconato","year":"2016","unstructured":"Zanconato, F., Cordenonsi, M. & Piccolo, S. YAP\/TAZ at the roots of cancer. Cancer Cell 29, 783\u2013803. https:\/\/doi.org\/10.1016\/j.ccell.2016.05.005 (2016).","journal-title":"Cancer Cell"},{"key":"90159_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13046-021-01827-8","volume":"40","author":"P Tocci","year":"2021","unstructured":"Tocci, P., Blandino, G. & Bagnato, A. YAP and endothelin-1 signaling: an emerging alliance in cancer. J. Exp. Clin. Cancer Res. 40, 27. https:\/\/doi.org\/10.1186\/s13046-021-01827-8 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"90159_CR33","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/s41467-019-11045-8","volume":"10","author":"P Tocci","year":"2019","unstructured":"Tocci, P. et al. \u03b2-arrestin1\/YAP\/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. Nat. Commun. 10, 3196. https:\/\/doi.org\/10.1038\/s41467-019-11045-8 (2019).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90159-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90159-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90159-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T11:49:28Z","timestamp":1739620168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90159-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90159"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90159-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"30 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5626"}}